International Journal of Nanomedicine (Jul 2014)

Nanopharmacology in translational hematology and oncology

  • Tomuleasa C,
  • Braicu C,
  • Irimie A,
  • Craciun L,
  • Berindan-Neagoe I

Journal volume & issue
Vol. 2014, no. Issue 1
pp. 3465 – 3479

Abstract

Read online

Ciprian Tomuleasa,1,2,* Cornelia Braicu,1,* Alexandra Irimie,3 Lucian Craciun,1 Ioana Berindan-Neagoe1,4,51Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 2Department of Hematology, Ion Chiricuta Cancer Center, 3Department of Prosthetic Dentistry and Dental Materials, 4Department of Immunology, Iuliu Hatieganu University of Medicine and Pharmacy, 5Department of Functional Genomics and Experimental Pathology, the Oncological Institute “Prof Dr Ion Chiricuta”, Cluj-Napoca, Romania*These authors contributed equally to this workAbstract: Nanoparticles have displayed considerable promise for safely delivering therapeutic agents with miscellaneous therapeutic properties. Current progress in nanotechnology has put forward, in the last few years, several therapeutic strategies that could be integrated into clinical use by using constructs for molecular diagnosis, disease detection, cytostatic drug delivery, and nanoscale immunotherapy. In the hope of bringing the concept of nanopharmacology toward a viable and feasible clinical reality in a cancer center, the present report attempts to present the grounds for the use of cell-free nanoscale structures for molecular therapy in experimental hematology and oncology.Keywords: hematological malignancies, nanoparticles, translational medicine